Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
LEAD is the most structurally ambitious ACO model CMS has ever constructed — and its ambition is precisely what creates both its strategic value and its execution risk.
The defining architectural choice is the 10-year performance period without rebasing. Every prior CMS ACO model has reset benchmarks periodically, creating the "ratchet effect" that penalized successful ACOs by using their own efficiency gains against them in future benchmark years. LEAD explicitly breaks this cycle. Benchmarks are set using three historical base years, trended forward using a growth rate calibrated below projected Medicare expenditure growth but above actual observed ACO expenditure growth — the "wedge" that generates shared savings. For an ACO that achieves meaningful cost reduction in PY 2027–2029, that efficiency compounds for the remaining seven performance years without the benchmark floor being raised. This is the single most important economic feature of the model.
The convergence architecture embedded in benchmarking deserves close attention. CMS has signaled it intends to use LEAD's decade-long runway to begin the transition away from ACO-specific historical benchmarks toward regional rate books. The Regional Efficiency Adjustment compares an ACO's historical baseline to average Medicare spending in its region in Base Year 3, with caps of 3% of risk-standardized USPCC for lower-spending ACOs (those with prior MSSP participation within two years) and 5% for higher-spending ACOs in the same category. This creates a two-track incentive: higher-spending ACOs enter with more room to generate savings; lower-spending ACOs are protected but face a tighter upside ceiling early. By PY 2036, CMS expects spending patterns across both groups to have converged sufficiently to anchor a post-LEAD benchmark regime.
The CARA initiative is a genuine structural innovation that prior models lacked. By enabling CMS to administer episode-based risk arrangements between ACOs and their specialist Preferred Providers — covering acute medical, procedural, chronic condition, and falls prevention episodes — LEAD creates a mechanism for ACOs to extend financial accountability downstream without requiring specialists to independently navigate CMMI contracting. This is only available to Global Risk Option ACOs, which is not incidental. CMS is using CARA as an inducement for full-risk adoption.
The Substance Access BEI — allowing ACO participants to consult with beneficiaries about eligible hemp products at the ACO's own expense, with no CMS reimbursement — reflects the broader Trump administration/RFK Jr. priority around alternative wellness modalities. Its operational significance is minimal; its political and reputational signaling is not.
Hidden risk: The Medicaid integration planning phase (March 2026–December 2027) will identify only two states for partnership frameworks. ACOs outside those two states receive no Medicaid integration mechanism for the foreseeable future, leaving dual-eligible care coordination as an aspirational rather than operational feature for the vast majority of participants through at least 2028.
Minimum viable scale: Standard ACOs must maintain 5,000 aligned Original Medicare beneficiaries per performance year, with a minimum of 3,000 claims-based aligned beneficiaries in at least one base year. High Needs/ESRD-eligible ACOs qualify for reduced thresholds — starting at 1,000 total / 600 claims-based in PY 2027, scaling up to 1,600/1,000 by PY 2031. Newly Entering ACOs have phased alignment ramp requirements that reach standard thresholds by PY 2031.
Quality withhold mechanics: CMS withholds 3% of the Financial Benchmark as a quality withhold in every performance year. In PY 2027, this withhold is 100% pay-for-performance across five measures (ACR, UAMCC, DAH, TFU, CAHPS), each worth 0.60% of benchmark. For a mid-sized ACO with $80 million in total benchmark spend, the withhold is $2.4 million annually. Full recovery requires scoring at or above the 30th percentile on all five measures — a threshold achievable by most competent ACOs — but sub-30th percentile performance on any single measure costs $480,000 in unrecovered withhold. The High Performers Pool beginning in PY 2028 creates upside beyond the 3% withhold: 50% of all unearned withholds across the LEAD population fund HPP distributions, allocated per beneficiary-month to qualifying ACOs. High-performing ACOs in large LEAD cohorts could recover meaningfully above their 3% starting withhold.
dQM/eCQM bonus: Optional CBP and GSD reporting in PY 2027–2028 yields up to 2.5 percentage points added to the Total Quality Score (1.25 points per measure). On that same $80M benchmark, a 2.5-point quality score boost translates to approximately $60,000 in additional recovered withhold. Modest individually; material in aggregate across a large ACO portfolio.
Capitation cash flow: Primary Care Capitation (PCC) and Total Care Capitation (TCC) payments are prospective — meaning cash flows before services are rendered. This is structurally superior to reconciliation-based models for physician groups with thin operating margins. The Administrative Add-On provides additional prospective support. Global Risk ACOs electing TCC receive up to 100% of savings and absorb up to 100% of losses; Professional Risk ACOs share at 50%/50%. The break-even for a Global Risk ACO depends heavily on starting benchmark level — higher-spending ACOs with 15–25% above regional average costs have the most room to generate net-positive settlement while absorbing downside risk.
Reconciliation timing risk: Final Financial Settlement is annual with an optional Provisional Financial Settlement mid-year. ACOs must maintain financial guarantees (letters of credit or equivalent) covering potential shared losses. For Global Risk participants, this capital reserve requirement is a real balance sheet consideration — particularly for independent physician groups and smaller FQHCs.
Most advantaged: Physician-led medical groups currently in ACO REACH Global Risk, particularly those serving higher-spending populations with below-average quality scores that have room to improve. The abbreviated application pathway for PY 2026 ACO REACH participants removes friction; the no-rebasing structure protects accumulated efficiency gains. High Needs-focused organizations — home-based primary care, complex care practices, some FQHCs — benefit from tailored risk adjustment, reduced alignment minimums, and CARA's RISE falls prevention episode.
Materially advantaged: Rural Health Clinics and Critical Access Hospitals seeking ACO infrastructure for the first time. The model's explicit inclusion of non-physician providers, the transitional CEHRT pathway (one-year on-ramp, three-year deferral for advanced health IT systems), and lower Newly Entering ACO alignment minimums reduce barriers that have historically excluded these organizations.
Disadvantaged: Hospital-employed physician groups and health systems. CMS's evidence base explicitly notes that physician-led ACOs outperform hospital-led ones (citing CBO), and LEAD's design — capped specialist accountability, Participant TIN whole-practice participation requirements, 75% provider control of governing body — actively disadvantages health system administrative structures. Systems that use ACO participation as a loss-leader to steer referrals will find LEAD's preferred provider restrictions and anti-gaming convener rules (three-year look-back on TIN movement across ACOs) constraining.
MSSP interaction: LEAD prohibits simultaneous participation in MSSP. This is a forced choice for many established ACOs. MSSP's annual rebasing and lower financial risk levels will appeal to risk-averse organizations; LEAD's 10-year no-rebase structure and higher payment flexibility will appeal to those with strong cost management capabilities. Expect a bifurcation of the ACO market along sophistication and risk appetite lines.
Medicare Advantage interaction: LEAD applies exclusively to Original Medicare. MA plans are not participants. However, ACOs with significant dual-track populations (OM and MA) will face care management resource allocation decisions — LEAD's benefit enhancements and Part B cost-sharing support (available now) and Part D premium buy-down (available by 2029) are designed to make Original Medicare ACO alignment more attractive to beneficiaries, which could create friction with MA plans seeking to retain or grow enrollment.
Physicians: The prospective capitation structure — particularly PCC — is the most meaningful improvement over MSSP for independent and small group practices. Cash flow predictability enables staffing investments (care coordinators, social workers) without waiting for annual reconciliation. The CEHRT transitional pathway removes a barrier that has caused prior ACO dropouts. The mandatory Prevention and Quality Plan adds administrative burden in Year 1 (planning) but is designed to generate measurable ROI by Year 3 when engagement accountability kicks in.
Health systems: LEAD is not designed for them. The 75% provider-control governance requirement, the whole-TIN participation rule, and the prohibition on hospital-only TINs from serving as alignment anchors limit health system ACO structuring options. Systems that want LEAD participation will need to genuinely cede governance control to their employed physicians — a significant cultural and operational ask. Those that do participate will benefit from CARA's specialist integration framework, which aligns well with health system specialty service lines.
Hospitals: Peripheral participants at best. Hospitals can participate as Preferred Providers and access CARA episode risk arrangements, but they do not drive alignment, do not control governance, and face fee reductions when enrolled in capitation mechanisms. The model's explicit goal of reducing hospitalizations and ED visits is a direct revenue headwind for facilities. The only clear upside for hospitals is if LEAD ACO partnership generates downstream patient volume through preferred provider relationships — a commercially rational trade-off that requires careful network contracting.
MA Plans: LEAD's beneficiary engagement incentives — particularly the Part D premium buy-down by 2029 and Part B cost-sharing support — represent a competitive response to MA's supplemental benefit advantage. If LEAD successfully attracts beneficiaries back to Original Medicare through these mechanisms, MA plans in high-penetration markets face enrollment pressure. MA plans should monitor LEAD beneficiary alignment rates in their service areas as a leading indicator of competitive displacement risk.
LEAD applications closed May 17, 2026. Implementation Period: September 15–December 31, 2026. Performance Year 1 begins January 1, 2027. Contact: LEAD@cms.hhs.gov.